CRC Research Update

  • TREATMENT

    Dual Oral Regimen Shows Activity in KRAS G12C–Mutated Metastatic CRC

    A phase Ib/II trial evaluated the chemotherapy-free combination of ifebemtinib (a FAK inhibitor) plus garsorasib (a KRAS G12C inhibitor) in previously treated KRAS G12C–mutated metastatic colorectal cancer, showing encouraging antitumor activity with seven of 15 patients achieving partial responses in the single-arm phase. (The ASCO Post)

  • RESEARCH

    Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC

    Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development. (ESMO Gastrointestinal Oncology)

  • SCREENING

    Review Outlines Advances and Challenges to Colonoscopy Quality

    A new article in Gastrointestinal Endoscopy Clinics of North America outlines current advances, challenges, and best practices for high-quality colonoscopy, noting that colorectal cancer remains the third most common cancer by incidence and second most common cause of cancer-related death in the United States. (Gastrointestinal Endoscopy Clinics of North America)

  • LIVING WITH CRC

    Study Examines Attachment Style, Symptom Distress, and Depression in CRC Survivors

    A cross-sectional study of 90 colorectal cancer survivors who completed treatment within the past three months explored relationships among adult attachment styles, symptom distress, and depressive symptoms, and whether mindfulness moderates these associations. (Oncology Nursing Forum)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

  • Calcitriol Modulates Age-Dependent Drug Response in Patient-Derived Colorectal Organoids

    Researchers used paired patient-derived normal and tumor colorectal organoids to investigate how calcitriol (the active vitamin D metabolite) modulates chemotherapy response. Dose-response analyses revealed marked interpatient variability, with SN38 being more potent than 5-fluorouracil and oxaliplatin. (International Journal of Biological Sciences)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

  • Developing Quality Programs to Track Colorectal Cancer Screening

    A new article proposes features for an ideal tracking system to enhance screening program performance, noting that common issues include suboptimal return rates for stool-based tests, lack of timely colonoscopy after abnormal results, and surveillance recommendations inconsistent with guidelines. (Gastrointestinal Endoscopy Clinics of North America)

Research continues to advance our understanding of colorectal cancer across screening, treatment, and survivorship.